US President Donald Trump makes an announcement in the Oval Office of the White House in Washington, DC on Nov. 6, 2025.President Donald Trump on Thursday struck landmark deals with Eli Lilly and Novo Nordisk that could mark a turning point in how many people can access their costly blockbuster obesity drugs. Under the agreements, Medicare will start covering GLP-1s for obesity for certain patients for the first time beginning in mid-2026 – a shift that will open access to millions of older adults and could ...

On Thursday, Eli Lilly and Co. (NYSE:LLY) released data from a Phase 2 trial evaluating the safety and efficacy of eloralintide, an investigational once-weekly, selective amylin receptor agonist, in 263 obese adults with at least one obesity-related health issue and without type 2 diabetes.At 48 weeks, all treatment arms of eloralintide met the primary endpoint, demonstrating superior mean weight reductions from 9.5% to 20.1% compared to 0.4% with placebo using the efficacy estimand.In the trial, all doses ...

Group 1 - Edmund Ingham is a biotech consultant with over 5 years of experience in covering biotech, healthcare, and pharma sectors [1] - He has compiled detailed reports on more than 1,000 companies and leads the investing group Haggerston BioHealth, which caters to both novice and experienced biotech investors [1] - The Haggerston BioHealth group provides insights on catalysts, buy and sell ratings, product sales forecasts, integrated financial statements, discounted cash flow analysis, and market-by-market analysis for major pharmaceutical companies [1]

By Jacob Gronholt-Pedersen and Maggie Fick COPENHAGEN (Reuters) -Shares in Novo Nordisk and Eli Lilly slipped on Friday after both agreed with the U.S government to lower prices of their blockbuster GLP-1 weight-loss drugs. The deal announced on Thursday, ​covering Novo's Wegovy and Lilly's Zepbound, will reduce monthly prices for U.S. government programmes, including Medicare and Medicaid,‌ and cash payers to between $149 and $350, down from $500 to $1,000. It also grants them a three-year relief from ...

Investors.com will undergo scheduled maintenance from 10:00 PM ET to 2:00 AM ET and some features may be unavailable. We apologize for any inconvenience. Eli Lilly (LLY) is battling it out with Novo Nordisk (NVO) on weight-loss drugs. Eli Lilly makes obesity drug Zepbound and diabetes treatment Mounjaro, which also helps with weight loss. On Thursday, The White House announced deals with the two companies to lower prices on weight-loss drugs and allow them to be covered by Medicare and Medicaid. Eli Lilly s ...

Tesla CEO Elon Musk attends the Saudi-U.S. Investment Forum, in Riyadh, Saudi Arabia, May 13, 2025.Hamad I Mohammed | ReutersThis is CNBC's Morning Squawk newsletter. Subscribe here to receive future editions in your inbox.Here are five key things investors need to know to start the trading day:1. +$1 trillionThe richest man in the world is about to get a lot richer.Tesla shareholders approved CEO Elon Musk's nearly $1 trillion pay plan yesterday, with 75% voting in support of the proposal despite oppositio ...

花旗银行将礼来目标价从1190美元上调至1250美元。 ...

The White House’s deal with Eli Lilly and Novo Nordisk could expand access to weight-loss drugs — but the fine print suggests the biggest winners may still be the drugmakers, @lisamjarvis says (via @opinion) https://t.co/DY1bEs34NK ...

2025.11. 07 礼来公司表示，根据新协议，对于现金支付的患者，该公司的减重药替尔泊肽的最低剂量售价为每月299 美元，其他剂量的售价为每月449美元。 目前在美国，减重药价格是全球最高的，售价在500美元至1000美元不等，接近其他国家的三倍。为此， 美国政府一直在推动减重药价格与全球其他地区趋于一致。 此次谈判协议也将适用于未来即将批准的新一代口服减重药。根据美国TrumpRx网站信息，对于美国医保 覆盖的患者，减重注射剂和口服药的平均价格将从每月350美元或更低的价格起始，预计两年内将降至245 美元。 本文字数：677，阅读时长大约1分钟 作者 | 第一财经 钱童心 在与美国政府的医保谈判之后，礼来与诺和诺德的减重药价格全面步入"百美元"时代。 特朗普政府表示，此次医保谈判后将使美国患者为这些减重药支付的费用降至平均每月149美元至350美元 之间，从而让更多人能够获得这些疗法。 "你们看到了他倒地了，但他没事。我们把他送出去接受医生治疗，他现在没事了，"特朗普说。"所以我们 的工作稍微中断了一下。" 根据报道，昏倒的是诺和诺德公司的高管戈登·芬德利（Gordon Findlay）。白宫新闻秘书 ...

整理 | GLP1减重宝典内容团队 周四晚，特朗普亲自登台，宣布了一项足以改写美国药品市场格局的政策——政府已与制药巨头礼来公司和诺和诺德达成协议，将从2026年起 大幅下调GLP-1类肥胖药物的价格，并扩大公共医疗保险体系对这些药物的覆盖。 过去几年，Wegovy与Zepbound的零售价一直维持在每月1000至1350美元之间，意味着普通家庭若自费购买，一年要花费超过一万美元。特朗 普政府在记者会上承认，美国人正在为药价"支付全世界最高的代价"。 新的协议规定，自2026年起，符合条件的Medicare和Medicaid患者可以以每月约245美元的统一价格获得这类药物， 而符合报销资格的患者自 付额甚至将被压低至50美元左右。 这一调整将首次使减肥药正式进入联邦医保体系，预计约有10%的红蓝卡受益人能够纳入治疗范围。 这无疑是一次重大政策转向。多年来，美国政府在药价谈判中鲜少取得实质突破，而此次协议不仅涵盖医保支付，更延伸至直接面向消费者的 销售渠道。 根据计划，特朗普政府将在明年推出一个名为TrumpRx.gov的网络平台，公众可通过该平台以折扣价购买礼来与诺和诺德的GLP-1产品，包括 Zepboun ...